Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome

Dry eye syndrome (DES) is a common ophthalmological disease that decreases tear secretion and causes dryness, photophobia, pain, severe corneal rupture, and even blindness. Ocular and lacrimal gland inflammation is one of the pathological mechanisms underlying DES. Therefore, effective suppression o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yi-Zhou Chen, Zhi-Yu Chen, Yu-Jun Tang, Cheng-Han Tsai, Yu-Lun Chuang, Erh-Hsuan Hsieh, Lachlan Tucker, I-Chan Lin, Ching-Li Tseng
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	lutein eye drops dry eye syndrome anti-inflammation polyvinyl alcohol Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/f5b87aef4dd34103a6d704c40f0d3645
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5b87aef4dd34103a6d704c40f0d3645
record_format	dspace
spelling	oai:doaj.org-article:f5b87aef4dd34103a6d704c40f0d36452021-11-25T18:40:47ZDevelopment of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome10.3390/pharmaceutics131118011999-4923https://doaj.org/article/f5b87aef4dd34103a6d704c40f0d36452021-10-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1801https://doaj.org/toc/1999-4923Dry eye syndrome (DES) is a common ophthalmological disease that decreases tear secretion and causes dryness, photophobia, pain, severe corneal rupture, and even blindness. Ocular and lacrimal gland inflammation is one of the pathological mechanisms underlying DES. Therefore, effective suppression of inflammation is a crucial strategy for the treatment of DES. Lutein, commonly found in healthy foods, has anti-inflammatory effects in corneal or retina-related cells and may be a potential therapy for DES. The addition of lutein to artificial tears (AT) as an eye-drop formulation for DES treatment in a mouse model was studied in the present work. Polyvinyl alcohol (PVA) was used as a thickener to increase the viscosity of eye drops to prolong drug retention on the ocular surface. A WST-8 assay in human corneal epithelial cells (HCE-2) showed that a concentration of <5 μM lutein (L5) and <1% PVA (P1) maintained the cell viability at 80%. A real-time PCR showed that the inflamed human corneal epithelial cells (HCECs) cocultured with L5P1 had downregulated expression of inflammatory genes such as IL-1β, IL-6, and TNF-α. In a benzalkonium chloride- (BAC) induced DES mouse model, AT/L5P1 could repair damaged corneas, elevate tear secretion, increase the number of goblet cells, and inhibit the production of inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in the cornea. In conclusion, we demonstrate that lutein/PVA as eye drops could prolong the drug ocular retention time and effectively to decrease inflammation in DES mice. Therefore, lutein, obtained from eye drops, has a potential therapeutic role for DES.Yi-Zhou ChenZhi-Yu ChenYu-Jun TangCheng-Han TsaiYu-Lun ChuangErh-Hsuan HsiehLachlan TuckerI-Chan LinChing-Li TsengMDPI AGarticleluteineye dropsdry eye syndromeanti-inflammationpolyvinyl alcoholPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1801, p 1801 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lutein eye drops dry eye syndrome anti-inflammation polyvinyl alcohol Pharmacy and materia medica RS1-441
spellingShingle	lutein eye drops dry eye syndrome anti-inflammation polyvinyl alcohol Pharmacy and materia medica RS1-441 Yi-Zhou Chen Zhi-Yu Chen Yu-Jun Tang Cheng-Han Tsai Yu-Lun Chuang Erh-Hsuan Hsieh Lachlan Tucker I-Chan Lin Ching-Li Tseng Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
description	Dry eye syndrome (DES) is a common ophthalmological disease that decreases tear secretion and causes dryness, photophobia, pain, severe corneal rupture, and even blindness. Ocular and lacrimal gland inflammation is one of the pathological mechanisms underlying DES. Therefore, effective suppression of inflammation is a crucial strategy for the treatment of DES. Lutein, commonly found in healthy foods, has anti-inflammatory effects in corneal or retina-related cells and may be a potential therapy for DES. The addition of lutein to artificial tears (AT) as an eye-drop formulation for DES treatment in a mouse model was studied in the present work. Polyvinyl alcohol (PVA) was used as a thickener to increase the viscosity of eye drops to prolong drug retention on the ocular surface. A WST-8 assay in human corneal epithelial cells (HCE-2) showed that a concentration of <5 μM lutein (L5) and <1% PVA (P1) maintained the cell viability at 80%. A real-time PCR showed that the inflamed human corneal epithelial cells (HCECs) cocultured with L5P1 had downregulated expression of inflammatory genes such as IL-1β, IL-6, and TNF-α. In a benzalkonium chloride- (BAC) induced DES mouse model, AT/L5P1 could repair damaged corneas, elevate tear secretion, increase the number of goblet cells, and inhibit the production of inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in the cornea. In conclusion, we demonstrate that lutein/PVA as eye drops could prolong the drug ocular retention time and effectively to decrease inflammation in DES mice. Therefore, lutein, obtained from eye drops, has a potential therapeutic role for DES.
format	article
author	Yi-Zhou Chen Zhi-Yu Chen Yu-Jun Tang Cheng-Han Tsai Yu-Lun Chuang Erh-Hsuan Hsieh Lachlan Tucker I-Chan Lin Ching-Li Tseng
author_facet	Yi-Zhou Chen Zhi-Yu Chen Yu-Jun Tang Cheng-Han Tsai Yu-Lun Chuang Erh-Hsuan Hsieh Lachlan Tucker I-Chan Lin Ching-Li Tseng
author_sort	Yi-Zhou Chen
title	Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_short	Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_full	Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_fullStr	Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_full_unstemmed	Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
title_sort	development of lutein-containing eye drops for the treatment of dry eye syndrome
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f5b87aef4dd34103a6d704c40f0d3645
work_keys_str_mv	AT yizhouchen developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome AT zhiyuchen developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome AT yujuntang developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome AT chenghantsai developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome AT yulunchuang developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome AT erhhsuanhsieh developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome AT lachlantucker developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome AT ichanlin developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome AT chinglitseng developmentofluteincontainingeyedropsforthetreatmentofdryeyesyndrome
_version_	1718410871341842432

Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome

Ejemplares similares